Evolent Health (EVH) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

EVH Stock Forecast

Evolent Health stock forecast is as follows: an average price target of $22.50 (represents a 116.14% upside from EVH’s last price of $10.41) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

EVH Price Target

The average price target for Evolent Health (EVH) is $22.50 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $14.00. This represents a potential 116.14% upside from EVH's last price of $10.41.

EVH Analyst Ratings

Buy

According to 11 Wall Street analysts, Evolent Health's rating consensus is 'Buy'. The analyst rating breakdown for EVH stock is 0 'Strong Buy' (0.00%), 11 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Evolent Health Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jan 16, 2025	Kevin Caliendo	UBS	$14.00	$9.97	40.42%	34.49%
Jan 15, 2025	Jailendra Singh	Truist Financial	$20.00	$9.97	100.60%	92.12%
Jan 14, 2025	Sean Dodge	RBC Capital	$17.00	$11.96	42.14%	63.30%
Jan 10, 2025	Constantine Davides	JMP Securities	$18.00	$12.54	43.54%	72.91%
Nov 18, 2024	Mohan Naidu	Oppenheimer	$28.00	$12.59	122.40%	168.97%
Oct 17, 2024	Jeff Garro	Stephens	$38.00	$24.95	52.27%	265.03%
Aug 09, 2024	Jailendra Singh	Truist Financial	$33.00	$20.87	58.12%	217.00%
Jun 05, 2024	Sean Dodge	RBC Capital	$42.00	$22.04	90.56%	303.46%
May 14, 2024	Jailendra Singh	Truist Financial	$28.00	$23.75	17.89%	168.97%
Apr 17, 2024	Jessica Tassan	Piper Sandler	$51.00	$29.60	72.30%	389.91%
Mar 28, 2024	Richard Close	Canaccord Genuity	$44.00	$32.73	34.43%	322.67%
Aug 03, 2022		BTIG	$50.00	$35.21	42.01%	380.31%
May 09, 2022		Canaccord Genuity	$45.00	$26.91	67.22%	332.28%

The latest Evolent Health stock forecast, released on Jan 16, 2025 by Kevin Caliendo from UBS, set a price target of $14.00, which represents a 40.42% increase from the stock price at the time of the forecast ($9.97), and a 34.49% increase from EVH last price ($10.41).

Evolent Health Price Target by Period

	1M	3M	12M
# Anlaysts	4	5	11
Avg Price Target	$17.25	$19.40	$30.27
Last Closing Price	$10.41	$10.41	$10.41
Upside/Downside	65.71%	86.36%	190.78%

In the current month, the average price target of Evolent Health stock is $17.25, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 65.71% increase as opposed to Evolent Health's last price of $10.41. This month's average price target is down -11.08% compared to last quarter, and down -43.01% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jan 16, 2025	UBS	Buy	Buy	Hold
Jan 14, 2025	RBC Capital	Outperform	Outperform	Hold
Jan 10, 2025	JMP Securities	Outperform	Outperform	Hold
Jan 10, 2025	Needham		Buy	Initialise
Nov 18, 2024	Oppenheimer	Outperform	Outperform	Hold
Oct 10, 2024	KeyBanc		Overweight	Initialise
Oct 08, 2024	Stephens	Underperform	Underperform	Hold
Oct 08, 2024	Truist Financial	Buy	Buy	Hold
Oct 03, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 19, 2024	JMP Securities	Underperform	Underperform	Hold
Aug 19, 2024	Stephens	Market Outperform	Market Outperform	Hold
Jun 05, 2024	RBC Capital	Outperform	Outperform	Hold
Apr 17, 2024	Piper Sandler	Overweight	Overweight	Hold
Mar 28, 2024	Canaccord Genuity	Buy	Buy	Hold
Feb 23, 2024	Canaccord Genuity	Buy	Buy	Hold
Feb 23, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Oct 11, 2022	Piper Sandler	Overweight	Overweight	Hold
Aug 03, 2022	BTIG	Buy	Buy	Hold
May 09, 2022	Canaccord Genuity	Buy	Buy	Hold

Evolent Health's last stock rating was published by UBS on Jan 16, 2025. The company gave EVH a "Buy" rating, the same as its previous rate.

Evolent Health Financial Forecast

Evolent Health Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$427.69M	$382.43M	$352.58M	$319.94M	$297.06M	$248.36M	$222.47M	$222.06M	$215.07M	$271.92M	$264.59M	$238.63M	$247.28M	$236.53M	$220.14M
Avg Forecast	$748.13M	$729.26M	$714.71M	$700.67M	$648.32M	$638.56M	$631.51M	$622.89M	$651.31M	$627.17M	$636.75M	$600.83M	$542.45M	$509.38M	$460.71M	$434.35M	$372.93M	$356.76M	$298.79M	$286.78M	$233.94M	$226.00M	$216.56M	$212.79M	$261.66M	$263.78M	$241.17M	$238.60M	$233.63M	$217.90M
High Forecast	$894.64M	$872.08M	$854.68M	$837.89M	$775.29M	$763.62M	$755.18M	$724.87M	$658.31M	$628.91M	$636.90M	$600.83M	$548.91M	$509.46M	$550.94M	$519.41M	$390.89M	$356.76M	$298.79M	$286.78M	$233.94M	$226.00M	$216.56M	$212.79M	$261.66M	$263.78M	$241.17M	$238.60M	$233.63M	$217.90M
Low Forecast	$625.63M	$609.86M	$597.69M	$585.95M	$542.17M	$534.01M	$528.11M	$530.28M	$643.33M	$625.43M	$636.61M	$600.83M	$539.68M	$509.31M	$385.28M	$363.23M	$352.80M	$356.76M	$298.79M	$286.78M	$233.94M	$226.00M	$216.56M	$212.79M	$261.66M	$263.78M	$241.17M	$238.60M	$233.63M	$217.90M
# Analysts	3	3	4	5	4	5	2	7	10	9	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	15	9	9	16	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.98%	1.03%	0.99%	1.07%	1.04%	1.06%	0.98%	1.03%	1.01%	1.04%	1.00%	0.99%	1.04%	1.01%	1.01%

Evolent Health's average Quarter revenue forecast for Jun 23 based on 5 analysts is $460.71M, with a low forecast of $385.28M, and a high forecast of $550.94M. EVH's average Quarter revenue forecast represents a 7.72% increase compared to the company's last Quarter revenue of $427.69M (Mar 23).

Evolent Health EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	10	9	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	15	9	9	16	8
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-20.96M	$-24.70M	$-37.43M	$-1.72M	$-23.95M	$13.75M	$19.28M	$15.42M	$8.42M	$12.17M	$12.49M	$8.16M	$-14.73M	$-185.35M	$-56.06M	$-200.02M	$-7.33M
Avg Forecast	$-66.68M	$-65.00M	$-63.70M	$-62.45M	$-57.78M	$-56.91M	$-56.28M	$-55.52M	$-58.05M	$-55.90M	$-56.75M	$24.93M	$-48.35M	$-45.40M	$-41.06M	$22.67M	$91.61M	$5.30M	$13.74M	$4.26M	$3.47M	$3.35M	$3.21M	$20.61M	$3.88M	$3.92M	$3.58M	$-51.75M	$3.47M	$3.23M
High Forecast	$-55.76M	$-54.35M	$-53.27M	$-52.22M	$-48.32M	$-47.59M	$-47.07M	$-47.26M	$-57.34M	$-55.74M	$-56.74M	$29.92M	$-48.10M	$-45.39M	$-34.34M	$27.20M	$109.93M	$5.30M	$16.48M	$4.26M	$3.47M	$3.35M	$3.21M	$24.73M	$3.88M	$3.92M	$3.58M	$-41.40M	$3.47M	$3.23M
Low Forecast	$-79.74M	$-77.73M	$-76.17M	$-74.68M	$-69.10M	$-68.06M	$-67.31M	$-64.61M	$-58.67M	$-56.05M	$-56.76M	$19.95M	$-48.92M	$-45.41M	$-49.10M	$18.13M	$73.29M	$5.30M	$10.99M	$4.26M	$3.47M	$3.35M	$3.21M	$16.48M	$3.88M	$3.92M	$3.58M	$-62.10M	$3.47M	$3.23M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.46%	0.60%	-1.65%	-0.02%	-4.52%	1.00%	4.53%	4.44%	2.51%	3.79%	0.61%	2.10%	-3.76%	-51.77%	1.08%	-57.67%	-2.27%

3 analysts predict EVH's average Quarter EBITDA for Sep 22 to be $5.30M, with a high of $5.30M and a low of $5.30M. This is -61.49% lower than Evolent Health's previous annual EBITDA (Jun 22) of $13.75M.

Evolent Health Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	10	9	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	15	9	9	16	8
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-33.20M	$-41.41M	$-19.98M	$-11.35M	$2.12M	$-4.13M	$-5.35M	$3.05M	$-13.04M	$-9.11M	$-9.81M	$-14.63M	$-37.35M	$-203.52M	$-78.75M	$-198.10M	$-25.52M
Avg Forecast	$31.45M	$32.24M	$27.91M	$26.15M	$25.14M	$24.12M	$21.28M	$19.19M	$4.88M	$35.55M	$27.48M	$-19.58M	$19.12M	$11.83M	$17.79M	$-17.80M	$-33.54M	$13.60M	$-5.05M	$-229.38K	$955.70K	$-3.93M	$-5.57M	$-16.18M	$-5.30M	$-5.05M	$-11.36M	$-72.69M	$-4.13M	$-14.31M
High Forecast	$39.46M	$40.45M	$35.01M	$32.81M	$31.54M	$30.26M	$26.70M	$24.07M	$16.74M	$37.02M	$27.49M	$-15.66M	$22.60M	$14.84M	$22.32M	$-14.24M	$-26.83M	$13.60M	$-4.04M	$-229.38K	$955.70K	$-3.93M	$-5.57M	$-12.95M	$-5.30M	$-5.05M	$-11.36M	$-58.16M	$-4.13M	$-14.31M
Low Forecast	$24.76M	$25.38M	$21.97M	$20.59M	$19.79M	$18.99M	$16.75M	$15.10M	$-18.60M	$34.09M	$27.46M	$-23.50M	$17.38M	$9.31M	$14.01M	$-21.36M	$-40.25M	$13.60M	$-6.06M	$-229.38K	$955.70K	$-3.93M	$-5.57M	$-19.42M	$-5.30M	$-5.05M	$-11.36M	$-87.23M	$-4.13M	$-14.31M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.81%	-2.33%	1.12%	0.34%	0.16%	0.82%	23.32%	3.19%	3.32%	1.63%	0.61%	2.76%	7.40%	17.91%	1.08%	47.98%	1.78%

Evolent Health's average Quarter net income forecast for Dec 22 is $-33.54M, with a range of $-40.25M to $-26.83M. EVH's average Quarter net income forecast represents a -1679.99% decrease compared to the company's last Quarter net income of $2.12M (Sep 22).

Evolent Health SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	10	9	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	15	9	9	16	8
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$96.57M	$90.39M	$89.73M	$82.86M	$68.52M	$58.95M	$58.93M	$66.92M	$51.29M	$42.70M	$58.59M	$86.45M	$77.08M	$68.66M	$78.36M	$83.60M	$93.61M
Avg Forecast	$208.15M	$202.90M	$198.85M	$194.94M	$180.38M	$177.66M	$175.70M	$173.30M	$181.21M	$174.49M	$177.16M	$116.98M	$150.92M	$141.72M	$128.18M	$106.34M	$103.76M	$99.26M	$64.85M	$79.79M	$65.09M	$62.88M	$60.25M	$96.68M	$72.80M	$73.39M	$67.10M	$72.34M	$65.00M	$60.63M
High Forecast	$248.91M	$242.63M	$237.79M	$233.12M	$215.70M	$212.46M	$210.11M	$201.68M	$183.16M	$174.98M	$177.20M	$140.37M	$152.72M	$141.74M	$153.28M	$127.61M	$108.75M	$99.26M	$77.82M	$79.79M	$65.09M	$62.88M	$60.25M	$116.01M	$72.80M	$73.39M	$67.10M	$86.80M	$65.00M	$60.63M
Low Forecast	$174.07M	$169.68M	$166.29M	$163.02M	$150.84M	$148.57M	$146.93M	$147.54M	$178.99M	$174.01M	$177.12M	$93.58M	$150.15M	$141.70M	$107.19M	$85.07M	$98.16M	$99.26M	$51.88M	$79.79M	$65.09M	$62.88M	$60.25M	$77.34M	$72.80M	$73.39M	$67.10M	$57.87M	$65.00M	$60.63M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.68%	0.71%	0.84%	0.80%	0.69%	0.91%	0.74%	1.03%	0.82%	0.71%	0.61%	1.19%	1.05%	1.02%	1.08%	1.29%	1.54%

Evolent Health's average Quarter SG&A projection for Dec 23 is $150.92M, based on 8 Wall Street analysts, with a range of $150.15M to $152.72M. The forecast indicates a 56.29% rise compared to EVH last annual SG&A of $96.57M (Sep 23).

Evolent Health EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	10	9	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	15	9	9	16	8
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.30	$-0.37	$-0.19	$-0.11	$0.02	$-0.05	$-0.06	$0.03	$-0.15	$-0.11	$-0.12	$-0.17	$-0.44	$-2.38	$-0.92	$-2.36	$-0.30
Avg Forecast	$0.27	$0.28	$0.24	$0.23	$0.22	$0.21	$0.19	$0.17	$0.04	$0.31	$0.24	$0.24	$0.17	$0.10	$0.15	$0.17	$0.10	$0.12	$0.05	$-0.00	$0.01	$-0.03	$-0.05	$-0.07	$-0.05	$-0.04	$-0.10	$-0.13	$-0.04	$-0.12
High Forecast	$0.34	$0.35	$0.30	$0.29	$0.27	$0.26	$0.23	$0.21	$0.15	$0.32	$0.24	$0.30	$0.20	$0.13	$0.19	$0.21	$0.10	$0.12	$0.05	$-0.00	$0.01	$-0.03	$-0.05	$-0.07	$-0.05	$-0.04	$-0.10	$-0.13	$-0.04	$-0.12
Low Forecast	$0.22	$0.22	$0.19	$0.18	$0.17	$0.17	$0.15	$0.13	$-0.16	$0.30	$0.24	$0.19	$0.15	$0.08	$0.12	$0.13	$0.09	$0.12	$0.05	$-0.00	$0.01	$-0.03	$-0.05	$-0.07	$-0.05	$-0.04	$-0.10	$-0.13	$-0.04	$-0.12
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.91%	-2.39%	-1.11%	-1.13%	0.17%	-0.94%	29.90%	4.15%	4.37%	2.26%	1.85%	3.68%	10.00%	24.02%	7.02%	65.56%	2.40%

According to 4 Wall Street analysts, Evolent Health's projected average Quarter EPS for Dec 22 is $0.10, with a low estimate of $0.09 and a high estimate of $0.10. This represents a 388.58% increase compared to EVH previous annual EPS of $0.02 (Sep 22).

Evolent Health Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EVH	Evolent Health	$10.41	$22.50	116.14%	Buy
FORA	Forian	$2.33	$4.50	93.13%	Buy
SLP	Simulations Plus	$33.80	$56.00	65.68%	Buy
HCAT	Health Catalyst	$5.63	$9.00	59.86%	Buy
DH	Definitive Healthcare	$4.93	$6.08	23.33%	Hold
PRVA	Privia Health Group	$22.51	$23.67	5.15%	Buy
CERT	Certara	$13.89	$14.50	4.39%	Buy
HQY	HealthEquity	$108.80	$107.50	-1.19%	Buy

EVH Forecast FAQ

Is Evolent Health a good buy?

Yes, according to 11 Wall Street analysts, Evolent Health (EVH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 100.00% of EVH's total ratings.

What is EVH's price target?

Evolent Health (EVH) average price target is $22.5 with a range of $14 to $38, implying a 116.14% from its last price of $10.41. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Evolent Health stock go up soon?

According to Wall Street analysts' prediction for EVH stock, the company can go up by 116.14% (from the last price of $10.41 to the average price target of $22.5), up by 265.03% based on the highest stock price target, and up by 34.49% based on the lowest stock price target.

Can Evolent Health stock reach $20?

EVH's average twelve months analyst stock price target of $22.5 supports the claim that Evolent Health can reach $20 in the near future.

What is Evolent Health's current price target trend?

4 Wall Street analysts forecast a $17.25 price target for Evolent Health (EVH) this month, up 65.71% from its last price of $10.41. Compared to the last 3 and 12 months, the average price target increased by 86.36% and increased by 190.78%, respectively.

What are Evolent Health's analysts' financial forecasts?

Evolent Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.54B (high $3.02B, low $2.13B), average EBITDA is $-226M (high $-190M, low $-269M), average net income is $89.72M (high $112.57M, low $70.63M), average SG&A $707.04M (high $839.94M, low $593.88M), and average EPS is $0.781 (high $0.98, low $0.615). EVH's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.89B (high $3.46B, low $2.42B), average EBITDA is $-258M (high $-216M, low $-308M), average net income is $117.76M (high $147.74M, low $92.69M), average SG&A $804.83M (high $962.45M, low $673.06M), and average EPS is $1.03 (high $1.29, low $0.807).

Did the EVH's actual financial results beat the analysts' financial forecasts?

Based on Evolent Health's last annual report (Dec 2022), the company's revenue was $1.35B, beating the average analysts forecast of $1.32B by 2.79%. Apple's EBITDA was $7.36M, missing the average prediction of $114.9M by -93.59%. The company's net income was $-18.701M, missing the average estimation of $-25.221M by -25.85%. Apple's SG&A was $269.27M, missing the average forecast of $347.65M by -22.55%. Lastly, the company's EPS was $-0.2, missing the average prediction of $0.263 by -176.09%. In terms of the last quarterly report (Mar 2023), Evolent Health's revenue was $427.69M, missing the average analysts' forecast of $434.35M by -1.53%. The company's EBITDA was $-37.432M, missing the average prediction of $22.67M by -265.15%. Evolent Health's net income was $-19.982M, beating the average estimation of $-17.8M by 12.26%. The company's SG&A was $89.73M, missing the average forecast of $106.34M by -15.63%. Lastly, the company's EPS was $-0.19, missing the average prediction of $0.171 by -211.27%